- CRS Publications
- News
News
Authors:
Date:
Business Wire: August 25, 2016 – PALM BEACH GARDENS, FL, U.S.A. – Transdermal Delivery Solutions Corporation (TDSC), www.TDSC.us, announced today that transdermal delivery veteran Wallace K. “Wally” Reams has joined its Board of Advisors.
Reams (www.linkedin.com/in/wreams) led the acquisition of…
Authors:
Date:
PRNewswire: August 25, 2016 – WAYNE, PA, U.S.A. – Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing, and commercializing innovative treatments for pain and other conditions, today announced that researchers will…
Authors:
Date:
Business Wire: August 18, 2016 – GREENVILLE, NC, U.S.A. – Mayne Pharma (ASX: MYX) is pleased to announce it has acquired a portfolio of on-market dermatology foam assets from GSK for US$50.1 million. The foam assets include U.S. rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® ,…
Authors:
Date:
PRNewswire: August 17, 2016 – BOSTON, MA, U.S.A. – Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “company”), a women’s health therapeutics company, today announced that a recently completed phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for…
Authors:
Date:
Business Wire: August 16, 2016 – REYKJAVIK, Iceland – Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company’s patented solubilizing nanoparticle (SNP) drug delivery platform and the…
Authors:
Date:
Business Wire: August 10, 2016 – LEXINGTON, MA, U.S.A. – TARIS Biomedical, a company developing powerful and targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases, announced today the initiation of a phase 1b clinical trial of TAR-200 (GemRIS™,…
